• 1
    Taylor FB, Lockhart MS. Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res 1985; 37: 63949.
  • 2
    De Fouw NJ, Haverkate F, Bertina RM, Koopman J, Van Wijngaarden A, Van Hinsbergh VWM. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. Blood 1986; 67: 118992.
  • 3
    Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 1694854.
  • 4
    Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 860816.
  • 5
    Suenson E, Petersen LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 1986; 870: 5109.
  • 6
    Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1447784.
  • 7
    Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 218338.
  • 8
    Hendriks D, Scharpe S, Van Sande M, Lommaert MP. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 27785.
  • 9
    Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 1593744.
  • 10
    Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 9339.
  • 11
    Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis. Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 381523.
  • 12
    Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang R-J, Lin J-H, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90: 256573.
  • 13
    Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem 1996; 271: 166038.
  • 14
    Le Bonniec BF, Guinto ER, MacGillivray RTA, Stone SR, Esmon CT. The role of thrombin's Tyr-Pro-Pro-Trp motif in the interaction with fibrinogen, thrombomodulin, protein C, antithrombin III, and the Kunitz inhibitors. J Biol Chem 1993; 268: 1905561.
  • 15
    Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093100.
  • 16
    Von dem Borne PAKr, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 23237.
  • 17
    Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 212735.
  • 18
    Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 1286878.
  • 19
    Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.
  • 20
    Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80: 94955.
  • 21
    Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 229427.
  • 22
    Kokame K, Zheng X, Sadler JE. Activation of thrombin activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 121359.
  • 23
    Walker JB, Nesheim ME. A kinetic analysis of the tissue plasminogen activator and DSPAα1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J Biol Chem 2001; 276: 313848.
  • 24
    Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, Van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 19923.
  • 25
    Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 102130.
  • 26
    Schneider M, Nagashima M, Knappe S, Zhao L, Morser J, Nesheim M. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem 2002; 277: 994451.
  • 27
    Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 654758.
  • 28
    Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML. A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem 2002; 277: 2532936.
  • 29
    Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, Koschinsky ML. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003; 278: 92507.
  • 30
    Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1: 14754.
  • 31
    Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 891321.
  • 32
    Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004; 279: 133405.
  • 33
    Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 133339.
  • 34
    Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896904.
  • 35
    Neill EK, Stewart RJ, Schneider MM, Nesheim ME. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2004; 330: 33241.